Undifferentiated pancreatic carcinoma

Undifferentiated pancreatic carcinoma is a rare epithelial neoplasm with high biological aggressiveness that belongs to the spectrum of exocrine pancreatic carcinomas. It is characterized by marked loss of the morphologic and architectural features typical of ductal adenocarcinoma, with often rapid growth, high mitotic activity, necrosis and a tendency to present at an advanced stage. In clinical practice, the term encompasses several high-grade histologic patterns, whereas one particular variant, undifferentiated carcinoma with osteoclast-like giant cells, is classified separately in modern systems because of its distinctive morphology and, in some series, clinical behavior that differs from conventional pleomorphic forms.

Clinically, the disease presents with symptoms often indistinguishable from those of the more common pancreatic carcinoma, including epigastric or back pain, weight loss, anorexia and asthenia. Tumors of the pancreatic head may cause obstructive jaundice, whereas pain and a cachectic syndrome are more common in tumors of the body and tail. Imaging may show large masses with necrotic and hemorrhagic areas, but diagnosis requires histologic confirmation when it alters the treatment pathway and rigorous definition of disease extent and resectability.

Treatment must necessarily be multimodal and, when the disease is resectable, is based on oncologic surgery integrated with systemic therapy according to the principles of exocrine pancreatic cancer, with attention to the frequent need for neoadjuvant strategies in borderline-resectable or locally advanced disease. In metastatic disease, management centers on systemic chemotherapy, pain control, management of cholestasis and nutritional support, because cachexia, thromboembolism and rapid functional decline substantially affect prognosis and treatment feasibility.

The epidemiology of undifferentiated pancreatic carcinoma is characterized by its marked rarity. In surgical series and pathology registries, this category accounts for a small proportion of exocrine pancreatic tumors and is observed far less often than conventional ductal adenocarcinoma. Estimating its true frequency is complicated by historical terminologic variability, differing inclusion of pleomorphic variants and the separation, in recent classifications, of undifferentiated carcinoma with osteoclast-like giant cells as a distinct entity.

Demographically, patients are most often adults and older people, with a sex distribution similar to that of common pancreatic carcinomas. The tumor may arise in the head, body or tail and frequently presents at an advanced stage. In some series, these neoplasms are larger and more often associated with necrosis, intratumoral hemorrhage or rapid enlargement, reflecting high biological aggressiveness.

The etiologic causes specific to undifferentiated carcinoma have not been established. No exposure has been demonstrated to be necessary and sufficient to cause this form. Consequently, the risk factors of clinical relevance are those shared with pancreatic ductal carcinoma and exocrine pancreatic neoplasms generally; they increase the probability of disease but do not explain the loss of differentiation.

Established risk factors include smoking, chronic pancreatitis, long-standing diabetes mellitus and obesity, with contributions from systemic inflammatory and metabolic processes. A subgroup of patients has a genetic predisposition related to hereditary syndromes or a strong family history of pancreatic carcinoma; in these settings, identifying the predisposing condition affects surveillance and family management, although it does not establish an exclusive link with the undifferentiated histologic subtype.

For undifferentiated pancreatic carcinoma, there are no population screening programs. The overall incidence of pancreatic carcinoma is too low to justify generalized screening, and no noninvasive tests have sufficient accuracy to identify high-grade tumors early without an excessive number of false-positive results. In clinical practice, early diagnosis depends on recognition of suggestive symptoms and timely use of dedicated imaging.

Surveillance is relevant instead for individuals at high risk of pancreatic carcinoma, such as carriers of predisposing hereditary syndromes or people with marked familial aggregation. In these patients, surveillance at specialized centers using MRI and endoscopic ultrasonography may permit earlier identification of high-risk lesions or early neoplasms. Surveillance is not directed toward a specific histologic subtype, because typing occurs only after a lesion has been detected.

After curative-intent treatment, post-treatment surveillance is essential because pancreatic carcinomas have a high probability of recurrence and undifferentiated forms may progress rapidly. The approach combines clinical visits, nutritional and metabolic management and periodic imaging, with intensity and frequency tailored to pathologic stage, surgical margins and lymph-node burden.

The biology of undifferentiated pancreatic carcinoma is characterized by marked loss of epithelial differentiation and a phenotype often associated with genomic instability, infiltrative aggressiveness and early dissemination. In many cases, the neoplasm retains a biological relationship with ductal carcinoma and shares driver alterations typical of exocrine pancreatic carcinomas. The undifferentiated component may emerge through dedifferentiation and cellular plasticity, with activation of epithelial–mesenchymal transition programs, chromatin remodeling and clonal selection under microenvironmental pressure.

The pancreatic microenvironment, dominated by desmoplastic stroma, hypoxia and local immunosuppression, may promote aggressive evolution and treatment resistance. Necrosis and hemorrhagic areas are common in undifferentiated forms, reflecting rapid growth and intratumoral vascular instability. In this setting, epithelial-marker expression may be reduced or focal, making lineage assignment difficult without an appropriate immunohistochemical panel.

Histologically, undifferentiated carcinoma may consist of highly pleomorphic cells, marked atypia, numerous mitoses and loss of glandular architecture. These tumors must be distinguished from primary sarcomas, lymphomas, metastases and high-grade neuroendocrine neoplasms because treatment and prognosis differ substantially. The osteoclast-like giant cell variant contains reactive multinucleated cells associated with a mononuclear neoplastic component, producing a distinctive morphology that requires expert interpretation.

Key pathologic and differential-diagnostic features

• Extensive sampling, especially of surgical specimens, to identify associated ductal components and transition areas.
• Immunohistochemistry with epithelial markers and exclusion panels for sarcoma, lymphoma and high-grade neuroendocrine neoplasia.
• Assessment of necrosis, perineural and lymphovascular invasion, margin status and lymph-node involvement.
• Distinction from the osteoclast-like giant cell variant, which has specific morphologic criteria.

Molecular characterization is particularly useful in advanced disease to identify subgroups with potential sensitivity to specific strategies, such as DNA-repair defects or rare actionable alterations. Nevertheless, undifferentiated biology is generally associated with high aggressiveness and a substantial risk of early progression, making multidisciplinary assessment and prompt decision-making essential.

The clinical manifestations of undifferentiated pancreatic carcinoma are largely nonspecific and overlap with those of more common pancreatic carcinomas. Epigastric or back pain is frequent and may be intense, consistent with perineural invasion and rapid growth. Weight loss that is unintentional, anorexia and fatigue reflect cancer cachexia, metabolic alterations and reduced food intake.

In tumors of the pancreatic head, common bile duct obstruction causes progressive jaundice with dark urine, pale stools and pruritus, sometimes complicated by cholangitis. In tumors of the body and tail, pain and systemic symptoms may predominate, resulting in later diagnosis. Endocrine and exocrine dysfunction, such as new-onset diabetes or rapid worsening of glycemic control and malabsorption with steatorrhea, may accompany presentation.

A clinically relevant feature shared by pancreatic carcinomas generally is the high thromboembolic risk, which may present as deep-vein thrombosis or pulmonary embolism. In advanced stages, metastatic disease may cause hepatomegaly, ascites, bone pain or dyspnea, with rapid functional decline. Physical examination may reveal jaundice, sarcopenia, epigastric tenderness and, in advanced cases, ascites or a palpable mass.

Clinical warning signs requiring prompt pancreatobiliary assessment

• Progressive obstructive jaundice with pruritus and dark urine.
• Persistent epigastric or back pain associated with weight loss.
• New-onset diabetes in adulthood or rapid worsening of pre-existing diabetes.
• Steatorrhea, malabsorption and nutritional decline without a clear alternative cause.
• Unexplained thromboembolic event in the setting of systemic or abdominal symptoms.

The clinical picture raises suspicion of a pancreatic neoplasm but cannot define the histologic subtype. Diagnostic confirmation and assessment of resectability depend on imaging and pathologic evaluation when indicated.

The diagnostic work-up of undifferentiated pancreatic carcinoma is based on high-quality dedicated imaging and rigorous definition of disease extent and resectability. Laboratory tests may show cholestasis in the presence of biliary obstruction and nonspecific inflammatory or nutritional abnormalities. CA 19-9 may be elevated, but it is nonspecific and must be interpreted cautiously, particularly before cholestasis has been drained.

Contrast-enhanced CT using a pancreatic protocol is the cornerstone because it assesses size, peripancreatic infiltration, relationships with major arteries and veins, and metastases, particularly in the liver and peritoneum. MRI and MRCP complete the evaluation when better characterization of the ductal system or indeterminate liver lesions is required. Endoscopic ultrasonography offers advantages for targeted sampling and locoregional assessment, with fine-needle aspiration or core biopsy.

Histologic confirmation is indicated when the result determines treatment strategy, especially in locally advanced or metastatic disease before systemic therapy. Diagnosis of undifferentiated forms may be difficult because epithelial-marker expression can be focal and morphology may mimic nonepithelial neoplasms. In such cases, review at an experienced center and use of appropriate immunohistochemical panels are essential to avoid misclassification.

According to oncology guidelines for exocrine pancreatic carcinoma, diagnosis and treatment planning require:

Rational sequence of investigations for suspected pancreatic carcinoma

• Pancreatic-protocol CT to define the mass, vascular relationships and metastases.
• MRI or MRCP when useful to complete evaluation of the biliary tract, pancreatic duct and liver.
• Multidisciplinary assessment of resectability and the indication for neoadjuvant therapy or upfront surgery.
• Histologic confirmation by endoscopic ultrasonography with targeted sampling when required before systemic therapy.
• Management of cholestasis with endoscopic drainage when indicated for safety and access to treatment.

In summary, diagnosis integrates dedicated imaging, definition of resectability, pathologic confirmation when required and complete pathologic reporting, with particular attention to the differential diagnosis of undifferentiated forms.

Staging of undifferentiated pancreatic carcinoma follows that of exocrine pancreatic carcinomas because it is a high-grade variant within the same oncologic compartment. The most widely used reference system is the AJCC/UICC TNM system (8th edition), which combines tumor size and local extent, lymph-node involvement and distant metastases. In parallel, defining resectability based on vascular involvement is crucial in clinical practice for selecting upfront surgery, neoadjuvant strategies or palliative treatment.

Prognosis is generally unfavorable and often worse than that of conventional stage-matched ductal carcinoma in available series, with a high risk of early recurrence and systemic progression. The main prognostic determinants include metastases, lymph-node burden, surgical margins, perineural invasion and nutritional status. Rapid functional decline and cachexia directly affect the ability to deliver effective therapy.

Stage groups for exocrine pancreatic carcinoma (AJCC/UICC 8th edition)

• Stage 0: intraepithelial neoplasia or carcinoma in situ confined to the ducts (Tis), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IA: tumor confined to the pancreas with a maximum diameter of ≤2 cm (T1), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IB: tumor confined to the pancreas with a maximum diameter of >2 cm and ≤4 cm (T2), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IIA: tumor confined to the pancreas with a maximum diameter of >4 cm (T3), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IIB: tumor measuring ≤2 cm (T1), >2 cm and ≤4 cm (T2), or >4 cm (T3), with regional lymph-node metastases in 1–3 nodes (N1) and no distant metastases (M0).
• Stage III: tumor measuring ≤2 cm (T1), >2 cm and ≤4 cm (T2), or >4 cm (T3), with regional lymph-node metastases in ≥4 nodes (N2) and no distant metastases (M0), or tumor involving major arterial vessels (T4), with any regional lymph-node status (any N) and no distant metastases (M0).
• Stage IV: tumor of any local extent (any T), with any regional lymph-node status (any N) and distant metastases present (M1).

Overall, prognosis is determined primarily by disease extent and resectability, but undifferentiated biology often requires a rapid, integrated therapeutic approach together with aggressive management of pain, cholestasis and nutritional decline.

Treatment of undifferentiated pancreatic carcinoma is based on a multimodal approach according to the principles of exocrine pancreatic carcinoma, with particular attention to its frequent clinical aggressiveness and the need to initiate therapy promptly. In resectable disease, surgery is the only potentially curative option and should be performed at a high-volume center. The procedure depends on tumor location, with pancreaticoduodenectomy for tumors of the head and distal pancreatectomy for tumors of the body or tail. The goals are negative margins and adequate lymph-node staging.

Systemic therapy is central and is often considered early. In borderline-resectable or locally advanced disease, neoadjuvant therapy is frequently used to increase the probability of R0 resection and select patients with more controllable tumor biology. After surgery, adjuvant therapy is generally indicated, unless contraindicated, to reduce recurrence risk. Radiotherapy may be used in selected settings for local control or symptom relief, based on multidisciplinary decision-making.

In metastatic disease, systemic chemotherapy is the cornerstone and is tailored to performance status and comorbidities. Endoscopic biliary drainage for clinically significant jaundice and pain control are often prerequisites for safe and effective treatment. Nutritional and metabolic management should be integrated from the outset because cachexia and sarcopenia reduce treatment tolerance and worsen outcomes.

Treatment goals and options according to the clinical setting

• Resectable disease: oncologic surgery with curative intent, followed by adjuvant systemic therapy whenever possible.
• Borderline-resectable or locally advanced disease: neoadjuvant therapy with reassessment of resectability and surgery in selected responders.
• Metastatic disease: systemic chemotherapy and supportive treatment for pain, cholestasis and nutritional decline.
• Integrated supportive care: prevention and treatment of thromboembolism, correction of cachexia and early palliative care in advanced disease.

Selection of systemic therapy follows established evidence for pancreatic carcinomas and must consider frailty, liver function, comorbidities and goals of care. When relevant molecular alterations are suspected or confirmed, genomic profiling may guide specific strategies, particularly within dedicated protocols or when the biological profile suggests therapeutic vulnerabilities.

Follow-up and post-treatment surveillance after curative-intent treatment are directed toward early identification of recurrence and management of functional sequelae. Regular clinical visits, nutritional and metabolic assessment and periodic imaging form the core of surveillance. Contrast-enhanced CT of the chest and abdomen is commonly used to detect locoregional recurrence and metastases.

Monitoring of CA 19-9 may be useful when elevated at baseline as an adjunct to clinical and radiologic follow-up, bearing in mind its limited specificity and possible interference from cholestasis. Management of exocrine pancreatic insufficiency with enzyme replacement therapy and control of postoperative or worsened diabetes are central to preserving quality of life and tolerance of any subsequent treatment.

In patients with advanced disease receiving systemic therapy, follow-up focuses on response, toxicity and maintenance of performance status, with particular attention to pain, nutrition and thromboembolic complications. Early integration of palliative care contributes to better symptom control and more effective planning of subsequent phases of care.

Long-term quality-of-life considerations in undifferentiated pancreatic carcinoma are influenced by disease severity, surgical outcomes and cumulative effects of systemic therapy. In operated patients, exocrine pancreatic insufficiency is common and is associated with steatorrhea, bloating, weight loss and deficiencies of fat-soluble vitamins; pancreatic enzymes and structured dietary support are crucial for functional recovery and reduction of sarcopenia.

Endocrine insufficiency with postoperative diabetes or worsening of pre-existing diabetes may impair energy, physical activity and independence, requiring ongoing diabetes follow-up. Fatigue, peripheral neuropathy and chemotherapy-related gastrointestinal disturbances may persist and limit work capacity and social relationships. In parallel, anxiety related to recurrence risk and perceived uncertainty, particularly relevant in pancreatic neoplasms, supports integrated psycho-oncology care.

Multidisciplinary care involving oncology, surgery, clinical nutrition, pain medicine, diabetology and rehabilitation facilitates preservation of function, treatment adherence and quality of life over time, especially in patients with complex digestive sequelae or a need for prolonged symptom control.

Complications of undifferentiated pancreatic carcinoma arise from local progression, metastatic dissemination and treatment effects. Biliary obstruction with jaundice and cholangitis is common in tumors of the head and requires prompt drainage. Severe pain caused by perineural invasion and involvement of nerve plexuses may be refractory and require multimodal strategies, including neurolytic procedures. Cancer cachexia, malnutrition and pancreatic insufficiency impair performance status and treatment tolerance.

After surgery, complications include pancreatic fistula, infections, abdominal fluid collections, bleeding and delayed gastric emptying, potentially resulting in prolonged hospitalization and temporary enteral or parenteral nutrition. In advanced stages, hepatic and peritoneal metastases may cause organ failure, ascites, subacute obstruction and rapid functional decline. Thromboembolic risk is high and may manifest as deep-vein thrombosis, pulmonary embolism or splanchnic thrombosis.

• Biliary complications: obstructive jaundice, cholangitis, stent dysfunction and the need for repeat endoscopic procedures.
• Postoperative complications: pancreatic fistula, fluid collections and infections, bleeding and delayed gastric emptying.
• Chemotherapy toxicity: neutropenia, infections, nausea, diarrhea, mucositis and peripheral neuropathy.
• Systemic complications: venous thromboembolism, cachexia, exocrine and endocrine pancreatic insufficiency, and refractory pain.

Prevention and management of complications require appropriate biliary drainage, early nutritional support, integrated pain control and close monitoring during systemic therapy. In advanced disease, early integration of palliative care optimizes symptom control and continuity of care.